Canaccord raised the firm’s price target on Wave Life Sciences (WVE) to $43 from $40 and keeps a Buy rating on the shares. The firm noted they announced that it has regained full rights to WVE-006 from GSK (GSK). The co cites GSK’s focus on large-scale diseases versus Wave’s ability to pursue smaller rare conditions.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Regained WVE-006 Ownership and Platform Validation Support Buy Rating and $33 Target
- Wave Life Sciences price target raised to $50 from $47 at Clear Street
- Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path
- Wave Life Sciences regains full rights to WVE-006
- 3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts